GLP-1 Receptor Agonist Use Surges Among UK Reproductive-Aged Women, Raising Urgent Pregnancy Outcome Concerns

The UK's accelerated rollout of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) for weight management has created a significant intersection between public health and reproductive health. With a substantial portion of the obese population being women of reproductive age, the increasing use of these potent metabolic drugs, which act via the GLP-1R pathway, raises critical questions about their impact on pregnancy. Current guidelines universally advise against GLP-1 RA use during pregnancy, recommending a two-month washout period. However, the scale of exposure in early pregnancy due to unintended conceptions remains largely unknown, posing a significant data gap.

This "Call to Action" letter analyzed UK private prescription data for GLP-1 RAs from an online weight management provider between November 2024 and October 2025. Researchers quantified monthly prescription pack volumes and assessed the age and gender distribution of 113,630 users. The objective was to estimate the proportion of women of reproductive age (defined as 18-45 years) potentially exposed to GLP-1 RAs, thereby highlighting the urgent need for robust data on pregnancy outcomes following such exposure.

Analysis revealed a substantial increase in private GLP-1 RA prescriptions for weight loss in the UK. By July 2025, 2.4 million monthly packs were prescribed privately for higher doses. This growth rate averaged over 20% monthly since the late 2023 launch. Crucially, demographic data from 113,630 private users indicated that women constituted 79% of users. The age distribution showed significant use among reproductive-aged women: 18-29 years (16.8%), 30-39 years (27.2%), and 40-49 years (24.3%). Summing the 18-45 years categories, researchers estimated that:

45% of all private GLP-1 RA users are likely women of reproductive age, creating a significant, unquantified risk for early pregnancy exposure. Existing guidelines recommend a two-month washout period due to the drug's half-life, but the scale of potential exposure underscores the urgency of quantifying actual pregnancy outcomes.